Crescenzo D’Alterio

Author

Crescenzo D’Alterio

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

C. D'Alterio, C. D’Alterio, Crescenzo D'Alterio, Crescenzo D’Alterio, Crescenzo D’alterio, D'Alterio Crescenzo, D'Alterio, Crescenzo, D’Alterio, Crescenzo

104

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"University of Naples Federico II University of Campania "Luigi Vanvitelli"Federico II University Hospital Institute of Biostructure and Bioimaging

About

Crescenzo D’Alterio is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	332
2	Immunology	5	5	231
3	Cell Biology	4	4	219
4	Health Sciences	1	1	77
5	Biochemistry	1	1	33

Crescenzo D’Alterio

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer Michele Cioffi, Crescenzo D’Alterio, Rosa Camerlingo, Scientific Reports	2015	106
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1 Crescenzo D’Alterio, Maria Buoncervello, Caterina Ieranò, Journal of Experimental & Clinical Cancer Research	2019	105
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells Gerardo Botti, Federica Fratangelo, Margherita Cerrone, Journal of Translational Medicine	2017	99
Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases Luigi Portella, Rosa Maria Vitale, Stefania De Luca, PLoS ONE Peptides RPreclinical DevelopmentNew Cxcr4MedicineImmunology	2013	85
Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer Sara Santagata, Maria Napolitano, Crescenzo D’Alterio, Oncotarget	2017	81
Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer Crescenzo D’Alterio, Claudia Consales, Maria Neve Polimeno, Current Cancer Drug Targets	2010	79
A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion Raffaela Fontanella, Alessandra Pelagalli, Anna Nardelli, Cancer Letters Regenerative MedicineBone Morphogenic ProteinMedicineStem Cell ResearchMesenchymal Stem Cell	2015	77
Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy Anna Maria Trotta, Alessandro Ottaiano, Carmela Romano, Cancer Immunology Research	2016	76
Differential role of CD133 and CXCR4 in renal cell carcinoma Crescenzo D’Alterio, Luca Cindolo, Luigi Portella, Cell Cycle	2010	68
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies Caterina Ieranò, Dario Righelli, Crescenzo D’Alterio, Journal for ImmunoTherapy of Cancer	2022	60

Page 1